Finnish pharmaceutical companies are short of APIs in hydroxychloroquine Previously, "COVID-19" (hydroxy) chloroquine had great side effects. FDA emergency authorization is condemned! " This paper reported that hospitals in Sweden were stopped because of the side effects of (hydroxy) chloroquine in treating COVID-19 patients, and then some hospitals in France announced that they would stop using (hydroxy) chloroquine in treating COVID-19 patients. Although there are many negative news about the treatment of COVID-19 with (hydroxy) chloroquine, there is no effective drug to treat COVID-19 at present, and (hydroxy) chloroquine, which is "the old drug and the new one", still plays an important role in the treatment of COVID-19. Recently, Amneal, a pharmaceutical company in Finland, said that they will speed up the production of hydroxychloroquine, but due to the ban in Finland, they will face the problem of insufficient raw materials in hydroxychloroquine. Earlier, Amneal promised to donate 20 million tablets of hydroxychloroquine before mid-April, but this promise may not be fulfilled due to the shortage of raw materials.
Trump's "bringing goods" is busy with the shortage of various drugs in the United States
In the United States, due to Trump Amway's shipment and FDA's emergency authorization, some lupus erythematosus patients who originally needed to use (hydroxy) chloroquine faced drug shortage. In addition, it is reported that Tylenol, a commonly used antipyretic drug, is in short supply in the United States due to the shortage of raw materials. According to FDA data, indolol, an analgesic drug, diclofenac, an ophthalmic drug, losapine, a narcotic drug, nalbuphine hydrochloride, parathyroid hormone, and triamcinolone acetonide, etc., have all announced shortages for the first time in the past six months. Previously, "the epidemic gradually improved? The article "The pharmaceutical industry is facing the most unexpected impacts" reports that the vast majority of American API manufacturers are located overseas including India, and 13%(230) of them are located in China. There has also been a "conspiracy theory" before. Stephen Hahn, director of the US Food and Drug Administration (FDA), said at the first time: "There is no evidence that there is any shortage of drugs due to China or other countries blocking the flow of key pharmaceutical ingredients into the US market."
Drug shortages and soaring prices in many European countries It is reported that the drug supply in some intensive care units in Britain is "somewhat tight", and medical supplies are in short supply. Some intensive care units have had to use alternative drugs to treat patients. Dr. Ron Daniels, an intensive care consultant in West Midlands County, said: "With the intensification of the epidemic, the quality of care for all intensive care patients, including COVID-19 patients, may be reduced. Patients who use ventilators need drugs to help stabilize blood pressure and blood circulation. Without this drug, it will greatly affect the treatment time and recovery chances of patients who use ventilators." A joint report by the German Federal Intelligence Agency, the Federal Criminal Police Department, the Federal Constitutional Protection Office and the Federal Information Technology Security Office mentioned that due to the impact of the global ban, antibiotics and their raw materials in Germany are facing a shortage problem. Friedemann Schmidt, the chief pharmacist of Germany, said: "At present, Germany is indeed facing the problem of drug shortage. Because there are problems in manufacturing and transporting drugs abroad, people start to purchase and hoard these drugs in panic." Gernot Marx of the German Association of Anesthesiology and Intensive Care Medicine (DGAI) also confirmed that the price of drugs has soared. For example, the price of propofol anesthesia has increased 20 times from 1 Euro per ampoule to 20 Euro per ampoule. Chinese raw materials meet opportunities, or will catch up with India The epidemic situation in China has been controlled, and when the overseas epidemic broke out, China, as a big country of raw material drugs, had new opportunities under the situation of global shortage of raw material drugs. Xin Guobin, deputy minister of the Ministry of Industry and Information Technology of China, said at the joint prevention and control conference of the State Council: "China is the world's largest producer and the largest exporter in terms of vitamins, antibiotics, antipyretic and analgesic drugs, anti-infective drugs and sebum hormone drugs. The international market accounts for more than 50%." At present, the re-production rate of Chinese API enterprises and the yield of main products have exceeded 80%, and the output of some varieties has exceeded the level of the same period last year, especially the anti-epidemic drugs, which can ensure the international anti-epidemic demand. For example, hydroxychloroquine produced by Chongqing Kangle Pharmaceutical Co., Ltd. exported 4.9 tons of raw materials in 5 days. Although it is not realistic for China to overtake India's API industry during the epidemic, it will still make China's pharmaceutical industry more important in the world.